Welcome to our dedicated page for Apyx Medical SEC filings (Ticker: APYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Apyx Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Apyx Medical's regulatory disclosures and financial reporting.
Apyx Medical Corporation reported first-quarter 2026 net sales of $12.5 million, up 32.4% from $9.4 million a year earlier, driven mainly by its Surgical Aesthetics segment and the AYON body contouring system. Gross profit rose to $7.9 million, lifting gross margin to 63.5% from 60.1% as higher-margin surgical aesthetics products made up a larger share of revenue.
The company reduced its net loss attributable to stockholders to $2.1 million, or $0.05 per share, compared with a $4.2 million loss, or $0.10 per share, in the prior-year quarter. Operating cash outflow was modest at $0.6 million, and cash and cash equivalents were $31.1 million at March 31, 2026. Apyx carries a $37.5 million term loan under its Perceptive Credit Agreement at a 12.0% interest rate and remains subject to revenue and operating expense covenants.
Management highlights strong growth in Surgical Aesthetics, with segment sales up 36.1% to $10.7 million, and notes that international revenue increased to 35.1% of total sales. At the same time, the company continues to incur recurring net losses and expects near-term losses to continue, indicating an ongoing need to balance growth investments, debt obligations and potential future financing.
Apyx Medical Corporation reported strong first quarter 2026 growth with higher revenue and narrower losses. Sales rose to $12.5 million from $9.4 million, led by Surgical Aesthetics revenue of $10.7 million, up 36.1% year over year, and OEM revenue of $1.8 million, up 13.8%.
Gross profit increased to $7.9 million with gross margin improving to 63.5%. Net loss attributable to stockholders improved to $2.1 million, or $0.05 per share, compared with a $4.2 million loss, or $0.10 per share, a year earlier. Adjusted EBITDA loss narrowed to $0.3 million from $2.4 million.
The company ended March 31, 2026 with $31.1 million in cash and cash equivalents and raised full‑year 2026 total revenue guidance to a range of $59.0 million to $60.0 million, citing strong uptake of the AYON Body Contouring System and better‑than‑expected international demand.
Apyx Medical Corp Senior Vice President Moshe Citronowicz exercised a stock option to acquire 37,000 shares of common stock at $1.80 per share under the company’s 2015 Share Incentive Plan. Following the transaction, he directly owns 493,504 shares of Apyx Medical common stock, indicating a routine compensation-related increase in his equity stake.
Apyx Medical Corporation reports its annual results highlighting ongoing operating losses alongside new product launches and financing actions. For the year ended December 31, 2025, it recorded a loss from operations of $6.4 million and used $8.0 million of cash in operations, while holding $31.7 million in cash and cash equivalents.
The company advanced its surgical aesthetics portfolio, receiving 510(k) clearance for its AYON body contouring system and beginning a commercial launch in September 2025, and it launched Renuvion in China after local clearance. It also completed a $7.0 million registered direct offering in 2024, a follow-on equity offering in 2025 with net proceeds of about $9.1 million, and put in place a shelf registration for up to $100 million of securities.
Apyx cut costs via a 2024 restructuring that reduced its U.S. workforce by nearly 25%, helping bring 2025 operating expenses below $40.0 million versus $48.2 million in 2024. As of December 31, 2025, it remained in compliance with covenants under its Perceptive Credit Agreement, which includes minimum revenue and maximum operating expense targets and a required $3.0 million cash balance.
Apyx Medical Corporation reported stronger results for the fourth quarter and full year 2025, helped by the U.S. launch of its AYON Body Contouring System. Fourth quarter revenue rose to $19.2 million from $14.2 million, with Surgical Aesthetics sales up 38.1% to about $16.7 million.
Net loss for the quarter narrowed to $1.3 million, or $0.03 per share, compared with $4.6 million, or $0.12 per share, and Adjusted EBITDA improved to a positive $0.7 million from a loss of $2.2 million. For 2025 overall, revenue increased 9.9% to $52.8 million, while net loss attributable to stockholders improved to $11.2 million from $23.5 million.
The company ended 2025 with $31.7 million in cash and cash equivalents and believes its cash can last through 2027. For 2026, it expects total revenue of $57.5 million to $58.5 million, driven by Surgical Aesthetics growth and partially offset by lower OEM revenue, as it continues scaling AYON in the U.S.
APYX Medical Corporation received an updated ownership disclosure from Nantahala Capital Management and its principals. As of December 31, 2025, the reporting group may be deemed to beneficially own 4,112,705 shares of APYX common stock, representing 9.99% of the outstanding shares.
This stake includes 138,614 shares that could be acquired within sixty days through warrant exercises. The shares are held in funds and separately managed accounts controlled by Nantahala, with voting and dispositive power shared among Nantahala, Wilmot B. Harkey, and Daniel Mack. The securities are reported as held in the ordinary course of business and not for the purpose of changing or influencing control of APYX.
Apyx Medical Corp Chief Operating Officer Shawn David Roman reported an option exercise. On January 27, 2026, he exercised a stock option to purchase 12,000 shares of Apyx common stock at $1.80 per share under the company’s 2015 Share Incentive Plan.
The 12,000 shares acquired are held indirectly through The Roman Family Revocable Trust, where he serves as both trustee and beneficiary. Following the transaction, the reported stock option position was reduced to 0 derivative securities, with 12,000 common shares beneficially owned through the trust.
Royce & Associates LP has filed an amended Schedule 13G reporting beneficial ownership of Apyx Medical Corporation common stock. The firm reports beneficial ownership of 2,443,035 shares, representing 5.95% of the outstanding common stock, as of the event date of 12/31/2025. Royce & Associates has sole power to vote and dispose of all of these shares and no shared voting or dispositive power.
The filing explains that the securities are held in one or more registered investment companies or other managed accounts that are investment management clients of Royce & Associates, an indirect majority-owned subsidiary of Franklin Resources, Inc. Royce & Associates states that the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Apyx Medical. The firm also disclaims any pecuniary interest and does not consider itself part of a group with Franklin Resources, its affiliates, or their principal shareholders.
Apyx Medical Corporation reported that it has released preliminary revenue results for the fourth quarter and full year ended December 31, 2025. The company disclosed this information through a press release dated January 12, 2026, which is furnished as Exhibit 99.1. The report clarifies that these disclosures are provided under a results of operations and financial condition item and are furnished rather than filed under securities laws, which affects how they are treated for liability purposes.